Xcout Intel
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing novel cardiovascular therapies.
Subscribe to see Imbria Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Imbria Pharmaceuticals, Inc. at a glance
Imbria Pharmaceuticals, Inc. is a biotechnology company headquartered in United States. It has raised at least $205.2M across the 5 funding rounds on record, 4 of them with a disclosed amount. Its most recent funding round, Series B, closed in November 2025. Xcout tracks 12 named people at Imbria Pharmaceuticals, Inc., including Alvin Shih (Chief Executive Officer).
Imbria Pharmaceuticals, Inc. leadership
- Alvin ShihChief Executive Officer
- Komal JoshiExecutive Officer
- Pavan K. CheruvuBoard Chair
- Alvin ShihDirector
- Andrew LevinDirector
- James JanuzziDirector
6 more named people on record for Imbria Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Imbria Pharmaceuticals, Inc. funding rounds
At least $205.2M raised across the 5 rounds on record (4 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | Undisclosed | 8 named | |
| Series B | $57.5M | 6 named | |
| Series B | $66.7M | 7 named | |
| SEC Form D filing | $40.7M | — | |
| SEC Form D filing | $40.2M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Imbria Pharmaceuticals, Inc. competitors
A few of Imbria Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, with additional operations in San Diego, California. The company focuses on the discovery and development of novel biopharmaceuticals for cardiovascular and other severe diseases.
Corteria Pharmaceuticals is a privately held biopharmaceutical company based in Paris, France, focused on developing first-in-class drugs for indications with high unmet medical need, particularly heart failure.
Centessa Pharmaceuticals LLC is a biotechnology research company headquartered in Boston, Massachusetts, United States. The company comprises leaders, innovators, and scientists dedicated to pursuing and developing transformational medicines for patients.
Imviva Biotech is a clinical-stage biotechnology company developing innovative therapies, including the TENACITY-01 CAR-T cell therapy clinical trial. The firm is associated with operations in Boston, Massachusetts, and works alongside other major biotechnology entities.
HeartBeat.bio is a biotechnology company founded in 2021 and located at the Vienna BioCenter in Austria, specializing in cardiac drug discovery. The company transforms cardiac drug recovery and development using innovative technologies originating from the Institute of Molecular Biotechnology (IMBA).
Checkmate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing proprietary technology to stimulate the immune system to combat cancer.
Get Imbria Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Imbria Pharmaceuticals, Inc. in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access